Retatrutide 10mg is the lower-dose formulation of the triple GIP/GLP-1/glucagon receptor triagonist Retatrutide (LY3437943, CAS: 2381089-83-2 | MW: ~4,681 Da). Optimised for preclinical dose-ranging investigations at lower concentrations, enabling characterisation of threshold effects and dose-response relationships for this triple receptor agonist. Supplied as lyophilised peptide at ≥98% purity.

Research Background

Triple receptor agonists represent the current frontier of incretin pharmacology. While dual GIP/GLP-1 agonists (tirzepatide class) have demonstrated robust preclinical and clinical effects, glucagon receptor co-agonism adds energy expenditure mechanisms through hepatic and thermogenic effects. The 10mg formulation provides the lower end of the dose range for establishing dose-response curves and exploring threshold effects in cellular and animal systems.

Dose-Range Research & Receptor Pharmacology

Complementary to the 20mg formulation, the 10mg vial enables:

• Full dose-response curve construction across the relevant concentration range
• Investigation of receptor-specific effects at sub-maximal occupancy levels
• Comparison against Tirzepatide 20mg (dual agonist) for relative potency characterisation
• Identification of minimum effective concentrations in cell-based assay systems

Storage & Handling

• Long-term storage: -20°C (lyophilised stable 18-24 months)
• Short-term storage: 2-8°C for up to 3 weeks after reconstitution
• Reconstitution: Sterile bacteriostatic water; gentle swirling
• Handling: Aliquot; avoid repeated freeze-thaw; standard peptide handling

Related Research Compounds

Higher-dose companion: Retatrutide 20mg. Comparative dual agonist: Tirzepatide 20mg.

For research use only. Not for human or animal consumption. Not a medicinal product.